Aurobindo Pharma Limited (BOM:524804)
India
· Delayed Price · Currency is INR 1,231.60
+5.80 (0.47%)
At close: Mar 6, 2026
Aurobindo Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 333,600 | 317,237 | 290,019 | 248,554 | 234,555 | 247,746 | Upgrade
|
| Other Revenue | -1,781 | - | - | - | - | - | Upgrade
|
| Revenue | 331,819 | 317,237 | 290,019 | 248,554 | 234,555 | 247,746 | Upgrade
|
| Revenue Growth (YoY) | 7.31% | 9.38% | 16.68% | 5.97% | -5.33% | 7.26% | Upgrade
|
| Cost of Revenue | 139,448 | 134,839 | 129,857 | 116,417 | 104,499 | 101,898 | Upgrade
|
| Gross Profit | 192,371 | 182,399 | 160,162 | 132,137 | 130,056 | 145,849 | Upgrade
|
| Selling, General & Admin | 50,502 | 45,470 | 40,434 | 36,560 | 35,751 | 36,576 | Upgrade
|
| Other Operating Expenses | 73,219 | 70,693 | 60,894 | 58,083 | 49,976 | 54,183 | Upgrade
|
| Operating Expenses | 140,579 | 132,074 | 116,247 | 107,018 | 96,992 | 101,313 | Upgrade
|
| Operating Income | 51,791 | 50,324 | 43,915 | 25,119 | 33,064 | 44,536 | Upgrade
|
| Interest Expense | -3,839 | -4,404 | -2,681 | -1,290 | -368.4 | -595.7 | Upgrade
|
| Interest & Investment Income | 3,564 | 3,564 | 2,883 | 1,485 | 349.7 | 223.7 | Upgrade
|
| Earnings From Equity Investments | -282.4 | -316.9 | -171.6 | -116.7 | -312.5 | -553.6 | Upgrade
|
| Currency Exchange Gain (Loss) | 496.9 | -226.5 | 387.8 | - | 699.6 | 1,036 | Upgrade
|
| Other Non Operating Income (Expenses) | 725.7 | 1,962 | 1,672 | 974.6 | 1,028 | 1,521 | Upgrade
|
| EBT Excluding Unusual Items | 52,456 | 50,903 | 46,006 | 26,173 | 34,461 | 46,167 | Upgrade
|
| Merger & Restructuring Charges | - | - | -986.6 | - | - | - | Upgrade
|
| Impairment of Goodwill | -96.2 | -96.2 | -27.4 | -70.3 | - | -4,349 | Upgrade
|
| Gain (Loss) on Sale of Investments | 335.3 | 335.3 | 1 | - | 290.8 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 234.9 | 132.3 | -400.2 | -1,411 | Upgrade
|
| Asset Writedown | -600.2 | -600.2 | -2,834 | -239.6 | -1,922 | - | Upgrade
|
| Other Unusual Items | -532 | 121.3 | 1,407 | 130.1 | 1,298 | 33,029 | Upgrade
|
| Pretax Income | 51,563 | 50,663 | 43,800 | 26,125 | 33,727 | 73,436 | Upgrade
|
| Income Tax Expense | 16,714 | 15,827 | 12,110 | 6,849 | 7,256 | 20,098 | Upgrade
|
| Earnings From Continuing Operations | 34,850 | 34,836 | 31,690 | 19,277 | 26,471 | 53,338 | Upgrade
|
| Minority Interest in Earnings | 20 | 23.1 | 40 | -1.5 | 10.4 | 10.2 | Upgrade
|
| Net Income | 34,870 | 34,859 | 31,730 | 19,275 | 26,482 | 53,348 | Upgrade
|
| Net Income to Common | 34,870 | 34,859 | 31,730 | 19,275 | 26,482 | 53,348 | Upgrade
|
| Net Income Growth | -0.12% | 9.86% | 64.62% | -27.21% | -50.36% | 87.51% | Upgrade
|
| Shares Outstanding (Basic) | 581 | 583 | 586 | 586 | 586 | 586 | Upgrade
|
| Shares Outstanding (Diluted) | 581 | 583 | 586 | 586 | 586 | 586 | Upgrade
|
| Shares Change (YoY) | -0.50% | -0.52% | - | - | - | - | Upgrade
|
| EPS (Basic) | 60.04 | 59.81 | 54.15 | 32.90 | 45.20 | 91.05 | Upgrade
|
| EPS (Diluted) | 60.04 | 59.81 | 54.15 | 32.90 | 45.19 | 91.05 | Upgrade
|
| EPS Growth | 0.38% | 10.44% | 64.62% | -27.21% | -50.37% | 87.51% | Upgrade
|
| Free Cash Flow | - | 19,568 | -3,458 | -170.5 | 29,636 | 18,911 | Upgrade
|
| Free Cash Flow Per Share | - | 33.57 | -5.90 | -0.29 | 50.58 | 32.27 | Upgrade
|
| Dividend Per Share | - | - | 4.500 | 3.000 | 9.000 | 4.000 | Upgrade
|
| Dividend Growth | - | - | 50.00% | -66.67% | 125.00% | 33.33% | Upgrade
|
| Gross Margin | 57.98% | 57.50% | 55.23% | 53.16% | 55.45% | 58.87% | Upgrade
|
| Operating Margin | 15.61% | 15.86% | 15.14% | 10.11% | 14.10% | 17.98% | Upgrade
|
| Profit Margin | 10.51% | 10.99% | 10.94% | 7.75% | 11.29% | 21.53% | Upgrade
|
| Free Cash Flow Margin | - | 6.17% | -1.19% | -0.07% | 12.63% | 7.63% | Upgrade
|
| EBITDA | 66,858 | 64,817 | 57,641 | 36,344 | 43,114 | 53,947 | Upgrade
|
| EBITDA Margin | 20.15% | 20.43% | 19.88% | 14.62% | 18.38% | 21.77% | Upgrade
|
| D&A For EBITDA | 15,067 | 14,492 | 13,726 | 11,225 | 10,050 | 9,411 | Upgrade
|
| EBIT | 51,791 | 50,324 | 43,915 | 25,119 | 33,064 | 44,536 | Upgrade
|
| EBIT Margin | 15.61% | 15.86% | 15.14% | 10.11% | 14.10% | 17.98% | Upgrade
|
| Effective Tax Rate | 32.41% | 31.24% | 27.65% | 26.21% | 21.52% | 27.37% | Upgrade
|
| Revenue as Reported | 337,182 | 323,456 | 295,593 | 251,460 | 237,758 | 251,555 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.